---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-007046"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:51:08.359710+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics Q3 2022 net loss $6.3M, cash $24.2M; pipeline and R&D day updates

## Summary
- Net loss $6.3M ($0.19/share) in Q3 2022 vs $14.3M ($0.59/share) in Q3 2021; nine-month loss $20.2M.
- Cash $24.2M at Sep 30, 2022, down from $38.9M at Dec 31, 2021; cash used in ops $14.4M in nine months.
- Five abstracts accepted at SITC 2022; R&D day Nov 10, 2022 featuring external experts.
- R&D expenses rose to $6.15M from $3.33M in Q3 2021 due to internal cGMP manufacturing scale-up.
- No revenue or guidance; clinical-stage biotech advancing allogeneic iNKT cell therapies.

## SEC filing metadata
- accession: 0001171843-22-007046
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000117184322007046/0001171843-22-007046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000117184322007046/f8k_110322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-007046
- JSON: https://secwatch.observer/filing/0001171843-22-007046.json
- Plain text: https://secwatch.observer/filing/0001171843-22-007046.txt

## Key facts
- Earnings Releases
  MiNK Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $6.3 million or $0.19 per share, EPS $0.19 per share.
  - Period: the quarter ended September 30, 2022
  - Net income: $6.3 million or $0.19 per share
  - EPS: $0.19 per share
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2022, was $6.3 million or $0.19 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840229/000117184322007046/0001171843-22-007046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.